Cat.No. : CSC-SC008515-1 Host Cell: HEK293T
| Cat. No. | CSC-SC008515-1 |
| Description | This cell line is engineered to stably express human lymphocyte activlymphocyte activating 3 (LAG3) in HEK293 cells. |
| Gene | LAG3 |
| Gene Species | Homo sapiens (Human) |
| Host Cell | HEK293T |
| Host Cell Species | Homo sapiens (Human) |
| Stability | Validated for at least 10 passages |
| Application | 1. Studying the interactions between immune cells and cancer cells 2. Studying the mechanisms of resistance to immune checkpoint blockade 3. High-throughput screening 4. Drug target validation |
| Quality Control | Negative for bacteria, yeast, fungi and mycoplasma. |
| Shipping | Dry ice |
| Storage | Liquid nitrogen |
| Revival | Rapidly thaw cells in a 37°C water bath. Transfer contents into a tube containing pre-warmed media. Centrifuge cells and seed into a 25 cm2 flask containing pre-warmed media. |
| Growth Properties | Cells are cultured as a monolayer at 37°C in a humidified atmosphere with 5% CO2. Split at 80-90% confluence, approximately 1:3-1:6. |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
Upon binding to Major Histocompatibility Complex Class II (MHCII) or Fibrinogen-like 1 (FGL1), the immune checkpoint receptor Lymphocyte activation gene-3 (LAG3) inhibits T cell function. Researchers investigated the role of LAG3 Stable Cell Line in elucidating the molecular structure and ligand engagement of Lymphocyte activation gene-3 (LAG3), an immune checkpoint receptor inhibiting T cell function. They determined the structures of human and murine LAG3 ectodomains, revealing dimeric assembly and epitope mapping. Insights into LAG3:FGL1 interface and ligand-mediated LAG3 clustering advance LAG3-based drug development, offering potential for disrupting T cell activation.
Figure 1. The role of LAG3 Stable Cell Line was examined by researchers, focusing on the colocalization of LAG3 and MHCII proteins on cell surfaces. LAG3 expression was analyzed using flow cytometry under various stimulations, and HLA-DR expression was assessed. Subsequently, the subcellular localization of LAG-3 and HLA-DR in HuT-78 cells was visualized using confocal microscopy, providing insights into their interaction dynamics. (Ming Q, et al., 2022)
A: NCI-H82 cells were likely chosen for their relevance to small cell lung cancer (SCLC) research and their potential to express CD274 (PD-L1) along with luciferase, enabling the study of PD-L1 expression dynamics and its correlation with tumor growth and response to therapy.
A: Stability was likely confirmed through methods such as luciferase assays, immunoblotting for CD274, or flow cytometry, with continuous monitoring to ensure consistent expression levels over time.
A: Characterization may involve analysis of luciferase activity as a surrogate marker for CD274 expression, correlation with tumor growth kinetics in vivo, and response to immune checkpoint blockade using PD-L1 inhibitors.
A: Quality control likely included validation of stable transgene integration, confirmation of CD274/Luc expression levels, assessment of luciferase activity, and monitoring for phenotypic stability and consistency.
A: Comparative analysis with patient-derived samples or in vivo models helps validate the relevance of CD274/Luc expression in immune evasion, tumor progression, and response to immunotherapy, guiding the development of personalized treatment approaches for SCLC patients.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
Exceptional reliability! The Human LAG3 Stable Cell Line in HEK293 cells offers consistent LAG3 expression, ensuring robust results in my immunology and cancer research.
Empowering advanced investigations! With stable LAG3 expression, I can explore immune checkpoint pathways and T cell regulation mechanisms with confidence, driving scientific innovation.
Impressive versatility! This cell line exceeds expectations, providing a reliable platform for studying LAG3-targeted therapies and immune modulation strategies in cancer immunotherapy.
Streamlining research processes! Its stable expression streamlines experimental workflows, simplifying data interpretation and accelerating scientific discoveries.
A pivotal asset! The Human LAG3 Stable Cell Line has significantly enhanced my research capabilities, offering valuable insights into LAG3-mediated immune responses and potential therapeutic interventions for cancer.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.
